A novel developmental mouse model of major depressive disorder
一种新型的重度抑郁症发育小鼠模型
基本信息
- 批准号:8473285
- 负责人:
- 金额:$ 17.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-05-24 至 2015-04-30
- 项目状态:已结题
- 来源:
- 关键词:AblationAddressAdultAmygdaloid structureAnimal ModelAntidepressive AgentsAnxietyAnxiety DisordersAreaBehaviorBehavioralBrainCandidate Disease GeneCause of DeathCharacteristicsChronicCognitiveComorbidityConsumptionCorticosteroneDepressive disorderDesipramineDevelopmentDiazepamDisciplineDiseaseDisease remissionEndocrineEtiologyExhibitsFigs - dietaryFluoxetineFoundationsGABA ReceptorGene ExpressionGene Expression ProfileGenesGeneticInterneuronsInvestigationLaboratoriesLifeLocomotionMajor Depressive DisorderMental DepressionMessenger RNAModelingMolecularMolecular ProfilingMonitorMood DisordersMusPathologyPatientsPhenotypePopulationPositioning AttributePrevalenceProteinase 3RNA SequencesResearchRoleSerumSocial InteractionSucroseSuicideSwimmingSyndromeTail SuspensionTestingTimeWorkage groupcingulate cortexcostcritical developmental perioddepressive symptomsdesigndevelopmental diseasedisabilityeffective therapyexperiencefollow-upfrontal lobegamma-Aminobutyric Acidloss of functionmouse modelneglectnext generationnon-geneticnovelpostnatalpublic health prioritiesreceptorresearch studyterationtraittranscriptome sequencingtransmission process
项目摘要
DESCRIPTION (provided by applicant): Anxiety Disorders and Major Depressive Disorder (MDD) are among the most prevalent and debilitating psychiatric syndromes. They exhibit extensive comorbidity and overlapping genetic origins, yet their molecular etiology and functional interrelationship are poorly understood. The vulnerability for both types of disorders i greatly exacerbated in early life, indicating that they are primarily developmental disorders. Mounting evidence points to a causal role of deficits in GABAergic transmission for both types of disorders. In particular, MDD is accompanied by reduced function and loss of GABAergic interneurons, reduced GABA concentration most pronounced in the melancholic subtype of MDD, and alterations in the subunit composition of the principal GABA receptors (GABAARs). Moreover, extensive analyses of GABAAR y2 subunit heterozygous mice by our lab suggest that modest developmental deficits in GABAergic transmission through these receptors may be causal for MDD. These mice exhibit behavioral, cognitive and cellular alterations expected of such a model, including endocrine and pharmacologic characteristics of melancholic MDD. Importantly, conditional gene ablation experiments indicate a postnatal developmental origin of this phenotype. Here we propose to use pharmacological manipulation of GABAergic transmission during postnatal development to generate a novel non-genetic mouse model of MDD that uniquely i) mimics a developmental etiology of MDD, ii) allows separation of depression-related from anxiety-related pathology, and iii) leads to a permanent/stable phenotype in adulthood that is amenable to investigation across disciplines (behavioral, cognitive, molecular, neuroanatomical, pharmacological, etc.). Preliminary experiment indicate that treatment of mice with diazepam (DZP) between postnatal day (P)10 and P21 leads selectively to increased anxiety-like behavior. By contrast, DZP treatment from P29-35 leads to selectively increased immobility under stressful conditions, which is the inverse of a pharmacological antidepressant-like effect. Thus, we hypothesize that anxiety- and depression- related behavioral traits are independently controlled by similar mechanisms during distinct postnatal developmental critical periods. We propose to establish P29-35 DZP treated mice as a novel and unique mouse model of MDD that is suited to monitor the developmental molecular sequelae underlying vulnerability to MDD in adulthood, and to distinguish the molecular etiology of MDD from that of heightened anxiety. In Aim 1 we will more fully establish the depressive like behavioral, endocrine and pharmacologic phenotype of P29-35 DZP treated mice. In Aim 2 we will use transcriptome analyses of the cingulate cortex of P10-24 and P29-35 DZP treated mice to compare the molecular signature of anxious vs. depressive like brain states. The work proposed will lay the foundation for an in depth analysis of the developmental mechanism underlying vulnerability to MDD.
描述(由申请人提供):焦虑症和严重抑郁症(MDD)是最普遍,令人衰弱的精神综合症之一。它们表现出广泛的合并症和重叠的遗传起源,但他们的分子病因和功能相互关系却鲜为人知。两种疾病的脆弱性我在早期生命中极大地加剧了它们,表明它们主要是发育障碍。安装证据表明,两种类型的疾病的缺陷在GABA能传播中的因果作用。特别是,MDD伴随着功能降低和GABA能中间神经元的丧失,在MDD的忧郁亚型中最明显的GABA浓度以及主要GABA受体(GABAARS)的亚基组成的改变。此外,我们实验室对GABAAR Y2亚基杂合小鼠的广泛分析表明,通过这些受体的GABA能传播中适度的发育缺陷可能是MDD的原因。这些小鼠表现出这种模型的行为,认知和细胞改变,包括忧郁症MDD的内分泌和药物特征。重要的是,条件基因消融实验表明该表型的产后发育起源。 Here we propose to use pharmacological manipulation of GABAergic transmission during postnatal development to generate a novel non-genetic mouse model of MDD that uniquely i) mimics a developmental etiology of MDD, ii) allows separation of depression-related from anxiety-related pathology, and iii) leads to a permanent/stable phenotype in adulthood that is amenable to investigation across disciplines (behavioral,认知,分子,神经解剖学,药理等)。初步实验表明,在产后日(P)10和P21之间用地西ep(DZP)治疗小鼠的小鼠有选择地导致焦虑样行为增加。相比之下,P29-35的DZP处理导致在压力条件下有选择地增加固定性,这是药理学抗抑郁样作用的相反。因此,我们假设焦虑和抑郁症相关的行为特征在不同的产后发育关键时期内由相似机制独立控制。我们建议建立P29-35 DZP处理的小鼠作为一种新颖而独特的MDD小鼠模型,适用于在成年期监测MDD的潜在脆弱性的发育分子后遗症,并区分MDD的分子病因与焦虑症的增强。在AIM 1中,我们将更充分地建立P29-35 DZP处理的小鼠的行为,内分泌和药理表型等抑郁症。在AIM 2中,我们将使用P10-24和P29-35 DZP处理的小鼠的扣带皮质的转录组分析来比较焦虑与抑郁症的分子特征。提出的工作将为对MDD脆弱性的发展机制进行深入分析奠定基础。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Defects in dendrite and spine maturation and synaptogenesis associated with an anxious-depressive-like phenotype of GABAA receptor-deficient mice.
- DOI:10.1016/j.neuropharm.2014.07.019
- 发表时间:2015-01
- 期刊:
- 影响因子:4.7
- 作者:Ren Z;Sahir N;Murakami S;Luellen BA;Earnheart JC;Lal R;Kim JY;Song H;Luscher B
- 通讯作者:Luscher B
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BERNHARD LUSCHER其他文献
BERNHARD LUSCHER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BERNHARD LUSCHER', 18)}}的其他基金
GABAergic Control of Depression Related Brain States
GABA 能控制抑郁相关的大脑状态
- 批准号:
9020824 - 财政年份:2013
- 资助金额:
$ 17.88万 - 项目类别:
GABAergic Control of Depression Related Brain States
GABA 能控制抑郁相关的大脑状态
- 批准号:
8653990 - 财政年份:2013
- 资助金额:
$ 17.88万 - 项目类别:
GABAergic Control of Depression Related Brain States
GABA 能控制抑郁相关的大脑状态
- 批准号:
8811475 - 财政年份:2013
- 资助金额:
$ 17.88万 - 项目类别:
GABAergic Control of Depression Related Brain States
GABA 能控制抑郁相关的大脑状态
- 批准号:
8531611 - 财政年份:2013
- 资助金额:
$ 17.88万 - 项目类别:
A novel developmental mouse model of major depressive disorder
一种新型的重度抑郁症发育小鼠模型
- 批准号:
8389229 - 财政年份:2012
- 资助金额:
$ 17.88万 - 项目类别:
Use of a mouse model of anxious depression to assess the safety of pediatric anti
使用焦虑抑郁小鼠模型评估儿科抗抑郁药物的安全性
- 批准号:
7832589 - 财政年份:2009
- 资助金额:
$ 17.88万 - 项目类别:
Use of a mouse model of anxious depression to assess the safety of pediatric anti
使用焦虑抑郁小鼠模型评估儿科抗抑郁药物的安全性
- 批准号:
7938728 - 财政年份:2009
- 资助金额:
$ 17.88万 - 项目类别:
Clustering and Synaptic Targeting of GABA-A Receptors
GABA-A 受体的聚类和突触靶向
- 批准号:
6782548 - 财政年份:2002
- 资助金额:
$ 17.88万 - 项目类别:
Clustering and Synaptic Targeting of GABA-A Receptors
GABA-A 受体的聚类和突触靶向
- 批准号:
6478440 - 财政年份:2002
- 资助金额:
$ 17.88万 - 项目类别:
Clustering and Synaptic Targeting of GABA-A Receptors
GABA-A 受体的聚类和突触靶向
- 批准号:
7110334 - 财政年份:2002
- 资助金额:
$ 17.88万 - 项目类别:
相似国自然基金
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Investigating the coordinated endothelial-epithelial interactions in adult hair cycle of mouse skin
研究小鼠皮肤成年毛发周期中协调的内皮-上皮相互作用
- 批准号:
10674132 - 财政年份:2023
- 资助金额:
$ 17.88万 - 项目类别:
A Novel VpreB1 Anti-body Drug Conjugate for the Treatment of B-Lineage Acute Lymphoblastic Leukemia/Lymphoma
一种用于治疗 B 系急性淋巴细胞白血病/淋巴瘤的新型 VpreB1 抗体药物偶联物
- 批准号:
10651082 - 财政年份:2023
- 资助金额:
$ 17.88万 - 项目类别:
The Role of Bone Sialoprotein in Modulating Periodontal Development and Repair
骨唾液酸蛋白在调节牙周发育和修复中的作用
- 批准号:
10752141 - 财政年份:2023
- 资助金额:
$ 17.88万 - 项目类别:
In vivo feasibility of a smart needle ablation treatment for liver cancer
智能针消融治疗肝癌的体内可行性
- 批准号:
10699190 - 财政年份:2023
- 资助金额:
$ 17.88万 - 项目类别:
LRP1 as a novel regulator of CXCR4 in adult neural stem cells and post-stroke response
LRP1 作为成体神经干细胞和中风后反应中 CXCR4 的新型调节剂
- 批准号:
10701231 - 财政年份:2023
- 资助金额:
$ 17.88万 - 项目类别: